Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunch-time regular insulin added to twice-daily mixed insulin for glycemic control in diabetes
PACTR201610001812290Unknown
- Sponsor
- Borg El-Arab Hospital
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of human insulin in diabetes mellitus (DM) (2 arms), sponsored by Borg El-Arab Hospital. Primary endpoint: HbA1c below 7%. Status: unknown.
02
Drugs
human insulin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on PACTR201610001812290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201610001812290.